A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Back to Search
Print
Bookmark Trial

NCT00994890

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Knee Osteoarthritis, Hip Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Osteoarthritis of the knee or hip based on American College of Rheumatology criteria with a radiographic (X ray) confirmation (a Kellgren Lawrence x-ray grade of ≥2);

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Body mass index (BMI) of >39 kg/m2;


- Pregnancy or intent to become pregnant


- Planned surgical procedure during the duration of the study


- History of clinically significant cardiovascular, central nervous system or
psychiatric disease


- Previous exposure to exogenous NGF or to an anti NGF antibody;


- Use of biologics other than study medication, Live or live-attenuated intranasal
vaccines (eg, Flumist), are allowable exceptions

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Knee Osteoarthritis, Hip OsteoarthritisStudy Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use" NCT00139776
  1. Huntsville, Alabama
  2. Peoria, Arizona
  3. Phoenix, Arizona
  4. Anaheim, California
  5. Huntington Beach, California
  6. Long Beach, California
  7. Orange, California
  8. Paramount, California
  9. Stockton, California
  10. Tustin, California
  11. Walnut Creek, California
  12. Whittier, California
  13. Wheatridge, Colorado
  14. Danbury, Connecticut
  15. New Milford, Connecticut
  16. Waterbury, Connecticut
  17. Ocala, Florida
  18. Palm Harbor, Florida
  19. South Miami, Florida
  20. Tampa, Florida
  21. Zephyrhills, Florida
  22. Decatur, Georgia
  23. Springfield, Illinois
  24. Dubuque, Iowa
  25. Dubuque, Iowa
  26. Lexington, Kentucky
  27. Madisonville, Kentucky
  28. Baltimore, Maryland
  29. Clinton, Maryland
  30. Frederick, Maryland
  31. Greenbelt, Maryland
  32. Wheaton, Maryland
  33. Brockton, Massachusetts
  34. Jefferson City, Missouri
  35. Jefferson City, Missouri
  36. Springfield, Missouri
  37. Lincoln, Nebraska
  38. Omaha, Nebraska
  39. Las Vegas, Nevada
  40. Las Vegas, Nevada
  41. Great Neck, New York
  42. Manlius, New York
  43. Mineola, New York
  44. New York, New York
  45. Rochester, New York
  46. Winston Salem, North Carolina
  47. Winston-Salem, North Carolina
  48. Cleveland, Ohio
  49. Columbus, Ohio
  50. Zanesville, Ohio
  51. Eugene, Oregon
  52. Beaver, Pennsylvania
  53. Camp Hill, Pennsylvania
  54. Duncansville, Pennsylvania
  55. Johnstown, Pennsylvania
  56. Philadephia, Pennsylvania
  57. Johnson City, Tennessee
  58. Knoxville, Tennessee
  59. New Tazewell, Tennessee
  60. Dallas, Texas
  61. Dallas, Texas
  62. Arlington, Virginia
  63. Renton, Washington
  64. Tacoma, Washington
  65. Yakima, Washington
  66. Yakima, Washington
  67. Milwaukee, Wisconsin
  68. Ham,
  69. Liege,
  70. Porto Alegre, RS
  71. Porto Alegre, RS
  72. Campinas, SP
  73. São Paulo, SP
  74. Calgary, Alberta
  75. Vancouver, British Columbia
  76. St. John's, Newfoundland and Labrador
  77. St. John's, Newfoundland and Labrador
  78. St. John's, Newfoundland and Labrador
  79. Corunna, Ontario
  80. Hamilton, Ontario
  81. London, Ontario
  82. Newmarket, Ontario
  83. North York, Ontario
  84. Sarnia, Ontario
  85. Toronto, Ontario
  86. Windsor, Ontario
  87. Charlottetown, Prince Edward Island
  88. Montague, Prince Edward Island
  89. Mirabel, Quebec
  90. Montreal, Quebec
  91. Rimouski, Quebec
  92. Sherbrooke, Quebec
  93. Ste-Foy, Quebec
  94. Saskatoon, Saskatchewan
  95. Santiago, RM
  96. Viña Del Mar, V Region
  97. Rancagua, VI Región
  98. Bogota, Cundinamarca
  99. Barranquila,
  100. Bogota,
  101. Bucaramanga,
  102. Joue Les Tours,
  103. L'Union,
  104. Poitiers,
  105. Tours,
  106. Randalstown, Co Antrim
  107. Newtownabbey, Co.Antrim
  108. Leslie, Fife
  109. Watford, Herts
  110. Canterbury, Kent
  111. Wigan, Lancs
  112. Bradwell Common, Milton Keynes
  113. Greenisland, Carrickfergus, Northern Ireland
  114. Barry, Vale of Glamorgan
  115. Pound Hill, Crawley, West Sussex
  116. Bradford on Avon, Wiltshire
  117. Midsomer Norton, Wiltshire
  118. Bangor,
  119. Bath,
  120. Belfast,
  121. Blackpool,
  122. Cardiff,
  123. Cookstown,
  124. Trowbridge,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Knee Osteoarthritis, Hip OsteoarthritisA Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections NCT00994890
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Long Term Study Of The Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip
Brief Summary This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg, and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times during the study treatment period.
Detailed Description Safety study of tanezumab in relief of osteoarthritis pain This study was terminated on 6 December 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Condition  ICMJE
  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
Intervention  ICMJE
  • Biological: Tanezumab 2.5 mg
    Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
    Other Name: Biological
  • Biological: Tanezumab 5 mg
    Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
    Other Name: Biological
  • Biological: Tanezumab 10 mg
    Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
    Other Name: Biological
Study Arms  ICMJE
  • Experimental: Tanezumab 2.5 mg
    Intervention: Biological: Tanezumab 2.5 mg
  • Experimental: Tanezumab 5 mg
    Intervention: Biological: Tanezumab 5 mg
  • Experimental: Tanezumab 10 mg
    Intervention: Biological: Tanezumab 10 mg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 16, 2010)		679
Original Estimated Enrollment  ICMJE
 (submitted: October 13, 2009)		600
Actual Study Completion Date  ICMJE December 2010
Actual Primary Completion Date December 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Osteoarthritis of the knee or hip based on American College of Rheumatology criteria with a radiographic (X ray) confirmation (a Kellgren Lawrence x-ray grade of ?2);

Exclusion Criteria:

  • Body mass index (BMI) of >39 kg/m2;
  • Pregnancy or intent to become pregnant
  • Planned surgical procedure during the duration of the study
  • History of clinically significant cardiovascular, central nervous system or psychiatric disease
  • Previous exposure to exogenous NGF or to an anti NGF antibody;
  • Use of biologics other than study medication, Live or live-attenuated intranasal vaccines (eg, Flumist), are allowable exceptions
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00994890
Other Study ID Numbers  ICMJE A4091043
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP